BioCentury | Feb 15, 2020
Product Development

WHO mapping out COVID-19 vaccines

Scientists from biopharma companies, universities and regulatory agencies met at the WHO Feb. 11-12 to draw a roadmap for the development of vaccines to protect against COVID-19 amid a rapidly shifting terrain. While knowledge about...
BC Extra | Jan 31, 2020
Clinical News

A dozen vaccine programs under way as WHO declares coronavirus public health emergency

WHO declared the coronavirus outbreak a Public Health Emergency of International Concern Thursday and called for China and countries around the world to take public health steps to contain the virus. WHO also stressed the...
BC Extra | Jan 27, 2020
Company News

J&J developing coronavirus vaccine, at least nine other vaccines under development

Two more companies have announced that they are developing vaccines to protect against the 2019-nCoV outbreak that was first detected in Wuhan, China, bringing the total number of vaccine development programs to at least 10....
BioCentury | Jan 25, 2020
Product Development

The race is on to develop therapies and vaccines for the coronavirus outbreak

Public release of the genetic sequence of the coronavirus first detected in Wuhan, China acted as a starter pistol, setting off a race to develop medical countermeasures. Beyond the potential for containing and hopefully eradicating...
BC Extra | Jan 23, 2020
Clinical News

Biopharma companies, academics, governments racing to develop medical countermeasures against novel coronavirus

The rapid sharing of the genetic sequence of the 2019 novel coronavirus (2019-nCoV), first identified in Wuhan, China, has sparked an extraordinary response from biopharma companies, academic researchers and governments. At least seven initiatives to...
BC Extra | Jan 22, 2020
Preclinical News

Moderna, Novavax among biotechs working on Wuhan virus -- but vaccine at least a year out

At least four groups have started to develop vaccines to protect against the 2019 Novel Coronavirus (2019-nCoV) that was first detected in Wuhan, China. Among companies working on a vaccine, Moderna Inc. (NASDAQ:MRNA) has partnered...
BC Extra | Oct 18, 2019
Clinical News

Novavax moving to crack egg-based flu vaccine market

In a bid to offer an alternative to the chicken egg-based influenza vaccine market, Novavax has launched a Phase III trial of a seasonal vaccine that is manufactured using an insect cell baculovirus system. The...
BC Extra | Oct 4, 2019
Company News

Icosavax’s self-assembling vaccine platform

Icosavax believes its computationally designed virus-like particles will open the clinically validated vaccine modality to a broader range of infectious diseases. The company expects its $51 million series A round, announced Thursday, to carry its...
BioCentury | Sep 27, 2019
Politics, Policy & Law

Trump administration to modernize flu vaccines via government buying power

The U.S. government is laying plans to harness its buying power and applied research capabilities to pull influenza vaccine development and manufacturing into the 21st century. The goals are to enhance protection against seasonal flu,...
BC Extra | Aug 14, 2019
Clinical News

Aug. 14 Clinical Quick Takes: Lynparza boosts ovarian cancer survival in first-line setting; plus Novavax, Gritstone and Solid

Lynparza extends PFS in first-line ovarian cancer  Lynparza olaparib plus bevacizumab as first-line maintenance therapy met the primary endpoint of significantly extending progression-free survival (PFS) vs. standard-of-care bevacizumab alone in advanced ovarian cancer patients in...
Items per page:
1 - 10 of 424
BioCentury | Feb 15, 2020
Product Development

WHO mapping out COVID-19 vaccines

Scientists from biopharma companies, universities and regulatory agencies met at the WHO Feb. 11-12 to draw a roadmap for the development of vaccines to protect against COVID-19 amid a rapidly shifting terrain. While knowledge about...
BC Extra | Jan 31, 2020
Clinical News

A dozen vaccine programs under way as WHO declares coronavirus public health emergency

WHO declared the coronavirus outbreak a Public Health Emergency of International Concern Thursday and called for China and countries around the world to take public health steps to contain the virus. WHO also stressed the...
BC Extra | Jan 27, 2020
Company News

J&J developing coronavirus vaccine, at least nine other vaccines under development

Two more companies have announced that they are developing vaccines to protect against the 2019-nCoV outbreak that was first detected in Wuhan, China, bringing the total number of vaccine development programs to at least 10....
BioCentury | Jan 25, 2020
Product Development

The race is on to develop therapies and vaccines for the coronavirus outbreak

Public release of the genetic sequence of the coronavirus first detected in Wuhan, China acted as a starter pistol, setting off a race to develop medical countermeasures. Beyond the potential for containing and hopefully eradicating...
BC Extra | Jan 23, 2020
Clinical News

Biopharma companies, academics, governments racing to develop medical countermeasures against novel coronavirus

The rapid sharing of the genetic sequence of the 2019 novel coronavirus (2019-nCoV), first identified in Wuhan, China, has sparked an extraordinary response from biopharma companies, academic researchers and governments. At least seven initiatives to...
BC Extra | Jan 22, 2020
Preclinical News

Moderna, Novavax among biotechs working on Wuhan virus -- but vaccine at least a year out

At least four groups have started to develop vaccines to protect against the 2019 Novel Coronavirus (2019-nCoV) that was first detected in Wuhan, China. Among companies working on a vaccine, Moderna Inc. (NASDAQ:MRNA) has partnered...
BC Extra | Oct 18, 2019
Clinical News

Novavax moving to crack egg-based flu vaccine market

In a bid to offer an alternative to the chicken egg-based influenza vaccine market, Novavax has launched a Phase III trial of a seasonal vaccine that is manufactured using an insect cell baculovirus system. The...
BC Extra | Oct 4, 2019
Company News

Icosavax’s self-assembling vaccine platform

Icosavax believes its computationally designed virus-like particles will open the clinically validated vaccine modality to a broader range of infectious diseases. The company expects its $51 million series A round, announced Thursday, to carry its...
BioCentury | Sep 27, 2019
Politics, Policy & Law

Trump administration to modernize flu vaccines via government buying power

The U.S. government is laying plans to harness its buying power and applied research capabilities to pull influenza vaccine development and manufacturing into the 21st century. The goals are to enhance protection against seasonal flu,...
BC Extra | Aug 14, 2019
Clinical News

Aug. 14 Clinical Quick Takes: Lynparza boosts ovarian cancer survival in first-line setting; plus Novavax, Gritstone and Solid

Lynparza extends PFS in first-line ovarian cancer  Lynparza olaparib plus bevacizumab as first-line maintenance therapy met the primary endpoint of significantly extending progression-free survival (PFS) vs. standard-of-care bevacizumab alone in advanced ovarian cancer patients in...
Items per page:
1 - 10 of 424